23May 2017

SkinBioTherapeutics PLC (AIM:SBTX) Extension of research contract with University of Manchester

SkinBioTherapeutics plc (AIM: SBTX), a life science company focused on skin health, announces that, as envisaged in the Company’s Admission Document dated 29 March 2017, it has agreed an eight month extension to its research contract with the University of Manchester to June 2018. This contract extension includes provision for the appointment of a second technician to the Company. This will increase the Company’s ability to develop its SkinBiotix® platform.

3May 2017

Optibiotix (AIM:OPTI) Presentation of abstract at conference

OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it has had an abstract accepted for presentation at the International Scientific Conference on Probiotics and Prebiotics in Budapest, Hungary from 20 – 22 June 2017 (IPC2017).

6Apr 2017

SkinBioTherapeutics Plc lists on FTSE (AIM:SBTX)

SkinBioTherapeutics plc (AIM: SBTX, the “Company”), a life science company focused on skin health, announces the commencement of dealings in its Ordinary Shares on AIM 5 March 2017 under the ticker code SBTX and the ISIN number: GB00BF33H870.

Page 1 of 212
DON’T MISS OUT!
Subscribe To Our Newsletter
Be the first to get latest updates and exclusive content straight to your email inbox.
Stay Updated
Give it a try, you can unsubscribe anytime.
Get the week’s best articles right in your inbox
Subscribe
Join 15K subscribers